课题基金 / 基金详情

Identification of Inhibitors of human Galactokinase (GALK) for the treatment of Galactosemia

Identification of Inhibitors of human Galactokinase (GALK) for the treatment of Galactosemia
用于治疗半乳糖血症的人半乳糖激酶 (GALK) 抑制剂的鉴定
批准号：
10004994
负责人：
Min Shen
金额：
$25.03万
依托单位：
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/10004994
关键词：
Animal ModelBiological AssayCellsCessation of lifeClassical galactosemiaDevelopmentDietDiseaseEnzymesGalactoseGalactosemiasGalectin 1HumanLeadLeftMeasurementMetabolicMetabolic DiseasesPathogenicityPatientsPharmaceutical ChemistrySymptomsbasegalactokinaseimprovedinhibitor/antagonistinterestliquid chromatography mass spectrometrynovel therapeutics

项目摘要

项目成果

Min Shen的其他基金

相似基金

相关文献

中文摘要
翻译
该项目旨在确定和开发Galk的抑制剂，作为治疗这种代谢性疾病的潜在的新疗法。 在此期间，合作小组继续进行其正在进行的药物化学活动，以提高Galk抑制活性。感兴趣的化合物已经被推进到基于细胞的分析和动物模型中，以进一步表征它们的细胞活性。此外，一种基于细胞的Gal1-p LC/MS分析已经在开发中，以实现对细胞内代谢物的直接测量，并提供一个急需的靶向活性的标记。
英文摘要
This project aims to identify and develop inhibitors of GALK as a potential novel therapy for this metabolic disease. During this period, the collaborative team continued with its ongoing medicinal chemistry campaign to improve GALK inhibitory activity. Compounds of interest have been advanced into cell-based assays and animal models to further characterize their cellular activity. In addition, a cell-based Gal1-p LC/MS assay has been in development to enable direct measurement of the metabolite in cells and provide a much needed marker of on-target activity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
qHTS for Inhibitors of Vif-A3F Interactions
Identification of Inhibitors of the Lipid Kinase PI5P4Ka/B as Potential Anti-Cancer Agents
qHTS for Inhibitors of Vif-A3G Interactions
Identification of Inhibitors of human Galactokinase (GALK) for the treatment of Galactosemia
海外基金